CHRS | Jotup

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Retrieved on:

Monday, April 8, 2024

B cell, Ligand, Patient, CHRS, Tumor microenvironment, LILRB2, Cancer, Macrophage, PD-1, Neonatal Fc receptor, IND, Phenotype, Neoplasm, Poster, ILT4, Vaccine

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data presented show CHS-1000 is a potent monoclonal antibody that binds selectively to human ILT4 (also known as LILRB2) with high affinity, efficiently blocking interaction with its ligands and reversing immunosuppressive functions, leading to activation of human dendritic cells and T cells and promoting polarization of macrophages to an inflammatory M1 phenotype.

Key Points:

“Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major contributor to tumor immune invasion and PD-1 resistance.
The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response.
“CHS-1000 is our first internally discovered development candidate, and we are excited to be filing the IND this quarter.
ILT4 and CD163, a marker of suppressive (M2) macrophages, are highly expressed in a broad range of solid tumors.

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Retrieved on:

Wednesday, March 13, 2024

UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.

Key Points:

UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.
Since commercial launch in May 2023, more than 727 accounts have ordered the Autoinjector presentation.
“Throughout 2023, Coherus demonstrated significant progress in transforming the Company’s business model and product portfolio for long-term sustainable growth,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer.
Coherus is introducing a guidance range of combined 2024 R&D and SG&A expenses from $250 to $265 million.

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Retrieved on:

Tuesday, March 5, 2024

PIN, Webcast, CHRS, Online shopping

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024.

Key Points:

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024.
Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.

Coherus Completes Divestiture of Ophthalmology Franchise

Retrieved on:

Monday, March 4, 2024

Nasopharyngeal carcinoma, Ophthalmology, CHRS, FDA, Sale, PD-1, Tumor microenvironment, Latham & Watkins, Ranibizumab

REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ: CHRS) today announced the completion of the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz, Inc. for upfront all-cash consideration of $170 million. This divestiture included Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams, and access to proprietary commercial software.

Key Points:

REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ: CHRS) today announced the completion of the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz, Inc. for upfront all-cash consideration of $170 million.
This divestiture included Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams, and access to proprietary commercial software.
Coherus received upfront, all-cash consideration of $170 million plus certain purchase price adjustments, which will be finalized following the closing pursuant to the agreement between Coherus and Sandoz.
J.P. Morgan Securities LLC acted as the Company’s financial advisor, and Latham & Watkins LLP acted as legal counsel to Coherus in connection with the transaction.

Coherus BioSciences Announces New Employment Inducement Grants

Retrieved on:

Friday, February 23, 2024

Employment, CHRS

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59, the closing trading price on the grant date.

Key Points:

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59, the closing trading price on the grant date.
One Executive Vice President level executive was granted an option to purchase 150,000 shares; and two additional non-officer employees were granted options to purchase an aggregate of 20,000 shares.
The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Retrieved on:

Wednesday, February 21, 2024

Incidence, CHRS, Febrile neutropenia, Luke the Evangelist, Infection, Empowerment, Risk, Needlestick injury, Patient, OBI, NDC, Cancer

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company's on-body injector (OBI) presentation of UDENYCA® (pegfilgrastim-cbqv), is successfully underway, with a broad distribution of accounts nationwide ordering this innovative device, and patients now accessing its benefits. UDENYCA is a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Key Points:

UDENYCA is a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.
“The ONBODY device is the third presentation in the UDENYCA franchise, which also includes a prefilled syringe and autoinjector.
Where a cancer diagnosis takes empowerment away from patients, UDENYCA gives it back.”
UDENYCA ONBODY is available through existing full-line and specialty distributors.
More details regarding UDENYCA ONBODY, including video instructions for ONBODY preparation and application, can be found at https://udenyca.com/hcp/onbody/ .

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

Retrieved on:

Monday, February 5, 2024

Growth, Consent, CHRS, Nasopharyngeal carcinoma, Sales management, Ophthalmology, Creditor, LP, Security (finance)

REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced it has entered into an agreement with Pharmakon Advisors, LP to revise the terms of its loan agreement entered in January 2022. Following the closing of the previously announced divestiture of the ophthalmology franchise to Sandoz, Coherus plans to prepay $175 million of $250 million principal balance in Q2 2024, leaving a residual balance of $75 million and reducing projected annual interest payments by about 70%.

Key Points:

REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced it has entered into an agreement with Pharmakon Advisors, LP to revise the terms of its loan agreement entered in January 2022.
“The divestiture of the ophthalmology franchise, when completed, is projected to provide us with the opportunity to improve our capital structure and reduce interest payment obligations by paying down a significant portion of the principal on term loan debt while renegotiating certain terms,” said Denny Lanfear, Chairman and Chief Executive Officer of Coherus.
“With three UDENYCA formats in the pegfilgrastim market, the launch of LOQTORZI into nasopharyngeal carcinoma, plus a promising immuno-oncology pipeline, they have positioned themselves for success as an oncology company.
Other terms of the Existing Loan Agreement, as amended by the Consent and Amendment, remain generally identical to those under the Existing Loan Agreement.

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

Retrieved on:

Monday, January 22, 2024

Hand, CHRS, Ophthalmology, PD-1, PIN, Latham & Watkins, FDA, Ranibizumab

REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced it has entered into an agreement to divest its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise, inclusive of CIMERLI and its supporting commercial infrastructure, to Sandoz for upfront, all-cash consideration of $170 million plus an additional amount for CIMERLI product inventory and subject to customary working capital adjustments at the closing date. This divestiture includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams, CIMERLI product inventory on hand, and access to proprietary commercial software.

Key Points:

This divestiture includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams, CIMERLI product inventory on hand, and access to proprietary commercial software.
“Since entering the ophthalmology market in 2022, we have gained strong market share and created significant value in a non-core therapeutic area by leveraging our buy-and-bill commercial expertise.
Closing is anticipated in the first half of 2024, subject to certain closing conditions and approvals, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
J.P. Morgan Securities LLC is acting as the Company’s financial advisor, and Latham & Watkins LLP is acting as legal counsel to Coherus in connection with the transaction.

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Retrieved on:

Thursday, January 18, 2024

REDWOOD CITY, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-targeting antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (uHCC). These data are being presented at the 2024 ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 at Moscone West in San Francisco, California. Interleukin (IL)-27 is an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment. Casdozo is a first-in-class antibody, and the only clinical stage immunomodulatory cytokine antagonist targeting IL-27.

Key Points:

These data are being presented at the 2024 ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 at Moscone West in San Francisco, California.
Interleukin (IL)-27 is an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment.
Casdozo is a first-in-class antibody, and the only clinical stage immunomodulatory cytokine antagonist targeting IL-27.
Coherus plans to evaluate the combination of casdozo/toripalimab-tpzi(Coherus’ anti-PD-1 antibody)/bev in future clinical trials.

HNO International, Inc. Celebrates Milestone Achievement: Successful Refueling of Toyota Mirai Using Innovative CHRS™ Technology

Retrieved on:

Tuesday, January 9, 2024

Hydrogen, Electrolysis, Toyota, CHRS, Partnership, Environment, Water, Mirai, AEM, Toyota Mirai, Renewable energy

HOUSTON, Jan. 9, 2024 /PRNewswire/ -- HNO International (HNOI) proudly announces the successful demonstration of clean hydrogen refueling of a Toyota Mirai utilizing its cutting-edge technology, the Compact Hydrogen Refueling Station (CHRS™).

Key Points:

HOUSTON, Jan. 9, 2024 /PRNewswire/ -- HNO International (HNOI) proudly announces the successful demonstration of clean hydrogen refueling of a Toyota Mirai utilizing its cutting-edge technology, the Compact Hydrogen Refueling Station (CHRS™).
We have successfully refueled a Toyota Mirai with clean hydrogen.
"This successful refueling of the Toyota Mirai using our CHRS marks a pivotal moment in our commitment to developing clean hydrogen infrastructure in the United States," stated Don Owens, Chairman of HNO International.
For more information about HNOI and its innovative CHRS technology, please visit www.hnointernational.com or contact us at [email protected] .